PA5-59644

antibody from Invitrogen Antibodies

Targeting: SLC5A2 SGLT2

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-59644

Provider

Invitrogen Antibodies

Product name

SGLT2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Immunogen sequence: FHEVGGYSGL FDKYLGAATS LTVSEDPAVG NISSFCYRPR PDSYHLL Highest antigen sequence identity to the following orthologs: Mouse - 89%, Rat - 91%.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

0.10 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.

D'Onofrio N, Sardu C, Trotta MC, Scisciola L, Turriziani F, Ferraraccio F, Panarese I, Petrella L, Fanelli M, Modugno P, Massetti M, Marfella LV, Sasso FC, Rizzo MR, Barbieri M, Furbatto F, Minicucci F, Mauro C, Federici M, Balestrieri ML, Paolisso G, Marfella R
Molecular metabolism 2021 Dec;54:101337

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 1 SIRT6 and SGLT2 expression in atherosclerotic plaques . ( A ) Representative confocal laser-scanning microscope images of SIRT6 and SGLT2 expression levels (red) in deparaffinized atherosclerotic plaques from non-diabetic patients, current SGLT2i users, and never SGLTi users. The von Willebrand factor (vWf, green) was used to properly localize the immunofluorescence signals in endothelial cells, while DAPI staining was used for nuclei counterstaining (blue). Scale Bar = 5 mum. (B) The ImageJ software carried out arbitrary fluorescence units (AFU) of SIRT6 and SGLT2. **p < 0.01 versus plaque specimen from patients without diabetes, #p < 0.05 never SGLT2i users. Protein expression levels of (C) SIRT6 (D) SGLT2 and (E) NF- B ( NF - kappaB ) in plaques from diabetic, non-diabetic, and diabetic SGLT2i-user patients. (F) Protein quantification was performed using beta-Actin and alpha-tubulin as the internal control. SGLT2 protein expression detected by using anti-SGLT2 antibody from Cell Signaling Technology. Lane 1 = protein ladder molecular weight markers, lane 2 = non-diabetic, lane 3 = never SGLT2i users, lane 4 = SGLT2i users. The analysis of densitometric intensity was calculated with ImageJ software and expressed as arbitrary units (AU) with **p < 0.01 versus patients without diabetes, #p < 0.05 versus never SGLT2i users. Figure 1